ZA201209566B - Novel glucagon like peptide analogs,composition,and method of use - Google Patents

Novel glucagon like peptide analogs,composition,and method of use

Info

Publication number
ZA201209566B
ZA201209566B ZA2012/09566A ZA201209566A ZA201209566B ZA 201209566 B ZA201209566 B ZA 201209566B ZA 2012/09566 A ZA2012/09566 A ZA 2012/09566A ZA 201209566 A ZA201209566 A ZA 201209566A ZA 201209566 B ZA201209566 B ZA 201209566B
Authority
ZA
South Africa
Prior art keywords
composition
peptide analogs
novel glucagon
glucagon
novel
Prior art date
Application number
ZA2012/09566A
Other languages
English (en)
Inventor
Shaojing Hu
Yanping Wang
Yunyan Hu
Xiangdong Zhao
Yinxiang Wang
Fenlai Tan
Cunbo Ma
Hong Cao
Wei Long
Lieming Ding
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of ZA201209566B publication Critical patent/ZA201209566B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
ZA2012/09566A 2010-05-17 2012-12-14 Novel glucagon like peptide analogs,composition,and method of use ZA201209566B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/000692 WO2011143788A1 (en) 2010-05-17 2010-05-17 Novel glucagon like peptide analogs, composition, and method of use

Publications (1)

Publication Number Publication Date
ZA201209566B true ZA201209566B (en) 2013-08-28

Family

ID=44991143

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/09566A ZA201209566B (en) 2010-05-17 2012-12-14 Novel glucagon like peptide analogs,composition,and method of use

Country Status (13)

Country Link
US (1) US9487570B2 (enExample)
EP (1) EP2571897B1 (enExample)
JP (1) JP5819946B2 (enExample)
KR (1) KR101609302B1 (enExample)
CN (1) CN103124739B (enExample)
AU (1) AU2010353685B2 (enExample)
BR (1) BR112012029248B1 (enExample)
CA (1) CA2802931C (enExample)
ES (1) ES2528496T3 (enExample)
RU (1) RU2557301C2 (enExample)
SG (1) SG185604A1 (enExample)
WO (1) WO2011143788A1 (enExample)
ZA (1) ZA201209566B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011134284A1 (zh) * 2010-04-27 2011-11-03 浙江贝达药业有限公司 胰高血糖素样肽-1类似物及其应用
EP2820424B1 (en) 2012-01-24 2016-12-07 University of Massachusetts Soluble manf in pancreatic beta-cell disorders
WO2019082138A1 (en) * 2017-10-27 2019-05-02 Lorven Biologics Private Limited PROCESS FOR THE PREPARATION OF LIRAGLUTIDE USING RECOMBINANT SACCHAROMYCES CEREVISIAE
WO2020118843A1 (zh) * 2018-12-12 2020-06-18 四川利通科创生物医药科技有限公司 一种glp-1突变体及其制备方法和用途
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
CN110862448A (zh) * 2019-11-21 2020-03-06 浙江大学 两性离子多肽修饰的glp-1衍生物及其制备方法和应用
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
CN115124596A (zh) * 2021-12-24 2022-09-30 浙江和泽医药科技股份有限公司 一种全固相合成醋酸亮丙瑞林的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE60137876D1 (de) * 2000-06-16 2009-04-16 Lilly Co Eli Analoge des Glucagon-ähnlichen Peptids-1
GEP20063908B (en) 2001-10-18 2006-08-25 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US20050153287A1 (en) * 2001-10-19 2005-07-14 Yasunori Hayashi Nr3b nmda receptor subunit compositions and related methods
EP1494704A1 (en) * 2002-04-04 2005-01-12 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7557183B2 (en) * 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
KR101308912B1 (ko) * 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
EP1709071A4 (en) * 2004-01-08 2007-05-30 Theratechnologies Inc GLUCAGON LIKE PEPTIDE-1 ANALOGS WITH LONG PERFORMANCE
CN100503637C (zh) * 2004-04-14 2009-06-24 浙江贝达药业有限公司 胰高血糖素样肽类似物、其组合物及其使用方法
CN100535006C (zh) * 2004-09-06 2009-09-02 上海华谊生物技术有限公司 Glp-1类似物
JP2008525452A (ja) * 2004-12-22 2008-07-17 イーライ リリー アンド カンパニー Ｇｌｐ−１類似体融合蛋白質製剤
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
SI1881850T1 (sl) * 2005-05-13 2011-01-31 Lilly Co Eli Glp-1 pegilirane spojine
CA2621699A1 (en) * 2005-09-08 2007-03-15 Trustees Of Tufts College Stabilized glp-1 analogs
DE102005063375A1 (de) * 2005-09-15 2007-04-19 Schülke & Mayr GmbH Antimikrobielle Zubereitungen mit einem Gehalt an Octenidindihydrochlorid verkapselt in Liposomen
EP2007804B1 (en) * 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
CN101668535B (zh) * 2006-12-29 2017-07-28 益普生制药股份有限公司 Glp‑1药物组合物
ATE515943T1 (de) * 2007-09-07 2011-07-15 Janssen Pharmaceutica Nv Kombinationen aus pyrimethanil und silberverbindungen
GB0717399D0 (en) * 2007-09-07 2007-10-17 Uutech Ltd Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues

Also Published As

Publication number Publication date
CN103124739A (zh) 2013-05-29
JP2013527178A (ja) 2013-06-27
AU2010353685A8 (en) 2013-05-09
CN103124739B (zh) 2015-11-25
US20130203672A1 (en) 2013-08-08
US9487570B2 (en) 2016-11-08
AU2010353685B2 (en) 2014-09-25
KR20130039740A (ko) 2013-04-22
CA2802931C (en) 2016-10-04
AU2010353685A1 (en) 2013-01-10
ES2528496T3 (es) 2015-02-10
RU2012154322A (ru) 2014-06-27
EP2571897A1 (en) 2013-03-27
BR112012029248A2 (pt) 2020-06-02
EP2571897A4 (en) 2013-11-06
WO2011143788A1 (en) 2011-11-24
SG185604A1 (en) 2012-12-28
BR112012029248B1 (pt) 2021-09-28
JP5819946B2 (ja) 2015-11-24
RU2557301C2 (ru) 2015-07-20
CA2802931A1 (en) 2011-11-24
EP2571897B1 (en) 2014-11-05
KR101609302B1 (ko) 2016-04-06

Similar Documents

Publication Publication Date Title
HRP20180829T1 (hr) Spojevi tioacetata, pripravci i postupci za uporabu
EP2694095A4 (en) COMPOSITIONS COMPRISING GLUCAGON ANALOGUES AND METHODS OF MAKING AND USING THE SAME
IL250824B (en) Certain amino-pyrimidines, their assemblies, and methods of using them
ZA201206832B (en) Novel peptides and method for their preparation and use
EP2718317A4 (en) GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE ANALOGUE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
EP2580378A4 (en) MULTIPLEX SEQUENCING METHODS AND COMPOSITION
ZA201206838B (en) Novel glucagon analogues
ZA201406250B (en) Compositions of glp-1 peptides and preparation thereof
ZA201208578B (en) Composition,method and use
ZA201400490B (en) Arginine- free tnfr: fc- fusion polypeptide compositions and methods of use
PL2385029T3 (pl) Kompozycje i sposób cementowania odwiertów
PL2588491T3 (pl) Nowy peptyd i jego zastosowanie
EP2571897A4 (en) NOVEL GLUCAGON PEPTIDE ANALOGUES, COMPOSITION, AND METHOD OF USE
EP2570417A4 (en) THIENOPYRIDINE ESTER DERIVATIVE CONTAINING NITRILE, PREPARATION METHOD, USE AND COMPOSITION THEREOF
ZA201306905B (en) Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these
GB201210536D0 (en) Composition, use and method of preparation thereof
EP2651429A4 (en) NEUROPEPTIDE ANALOGUES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
LT2749168T (lt) Gofruota kompozicija ir jos naudojimas
ZA201209021B (en) Therapeutic peptide composition and method
IL234228B (en) Compositions of glp-1 peptides and preparation thereof
GB201002278D0 (en) composition and method of preparation